SV

Street Verdict

Analyst Scorecard

A record of what ICICI Securities Analysis said publicly, with the source. Not advice.

“Maintains a 'Reduce' call on Glenmark Pharmaceuticals with a revised target price of ₹1,300, down from the current market price of ₹1,383.9. The brokerage anticipates revenue, EBITDA, and PAT to grow at a CAGR of 10.3%, 15.0%, and 20.8% respectively, between FY25-27E, but has slightly reduced FY26/27E estimates due to slower growth in India. The target is based on 18x FY27E EPS.”

ICICI Securities Analysis’s track record (trackable calls only): 265 graded calls · 95% CI 41–52%

Glenmark Pharmaceuticals LtdBearishCalled 29 May 2025Graded 29 May 2026
Verdict:MISS

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹1,300, as stated.

Window: 12 months, the default when no time frame is stated.

Neither the target ₹1,300 was reached on a close by the end of the window. Miss.

The grader’s working: R4 TARGET_CALL: entered ₹1457.1 on 2025-05-30 (next trading session's close); neither target nor stop reached by window end 2026-05-29. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.

Tracking Glenmark Pharmaceuticals Ltd since this call

1-year tracking window
Read the original articleSee ICICI Securities Analysis’s full track record